May 21FundingBristol Myers Squibb’s $40B U.S. Investment Signals a Strategic Bet on Domestic ManufacturingAs global pharmaceutical supply chains face renewed scrutiny and U.S. healthcare costs continue to climb, Bristol Myers Squibb (BMS) is making a bold and strategic move: a $40 billion investment in U.S.-based manufacturing over the next decade.
Apr 24EconomicsWould a $5K ‘Baby Bonus’ Fix America’s Birth Rate—or Just Fuel the Fertility Industry?
